Cortical Disarray Measurement provides powerful biomarker that offers enhanced prognostic capabilities for predicting progression from MCI to dementia compared to traditional macrostructural markers.
Read our latest publication: oxfordbraindiagnostics.com/p…
2
82
As part of an international research consortium, Oxford Brain Diagnostics has been awarded a grant from The Michael J. Fox Foundation. Together with leading institutions, we’re advancing biomarkers to help detect pre-symptomatic Parkinson’s disease.
bit.ly/3FgfCNI
3
92
We’re proud to see our work in brain health featured by BBC News.
Global awareness is crucial in the fight against dementia, and we’re honoured to be part of the ongoing international dialogue focused on improving early diagnosis and patient care.
youtu.be/GKN_uIIRx5Y
2
73
We’re delighted to see our work in brain health featured on ABC Australia, where Dr Steven Chance, CEO of Oxford Brain Diagnostics, spoke about our technology - Cortical Disarray Measurement (CDM) technology.
Watch the full interview here: youtube.com/watch?v=bmm14voz…
2
66
Oxford Brain Diagnostics retweeted
BGF-backed biotech gains regulatory approval for early dementia diagnosis - will begin UK and US rollout 🧠🌍
@OxfordBrain @UniofOxford #biotech #technology #innovation #science #health #dementia #oxonnews #oxonhour #businessnews #businessintelligence
insidermedia.com/news/south-…
With a major investment round led by BGF in 2023 and following both FDA 510k clearance and UKCA self-certification for our CDM Insights, we’re now entering clinical deployment.
bit.ly/45x7WkG
1
37
Oxford Brain Diagnostics retweeted
Oxford Brain Diagnostics to roll out revolutionary dementia technology following UK and US regulatory approvals
bit.ly/3Zq6vAX
Dr Steven Chance, CEO of Oxford Brain Diagnostics, was interviewed on BBC Radio 4’s morning show and Radio 5 to discuss our innovative CDM technology.
Listen to the segment (48min-53min) to learn more about our work in brain health: bbc.co.uk/sounds/play/m002cp…
The Telegraph shines a spotlight on our CDM technology, which analyses standard MRI scans to provide valuable insights into brain health and timely detection of neurodegenerative diseases.
Read the full story here: bit.ly/3HsdfI2
40
Oxford Brain Diagnostics retweeted
Daily medtech news with Smarteeva: 27 May
☑️ @OxfordBrain(OBD) is gearing up to launch a software tool designed to evaluate the early signs of dementia by analysing MRI scans.
☑️ @route92med has announced that its HiPoint Reperfusion System, including the .088in HiPoint 88 aspiration catheter, has shown positive outcomes in the SUMMIT MAX trial compared to a conventional .074in catheter for endovascular stroke thrombectomy.
☑️ @MTFBiologics, in partnership with biologic solutions provider Kolosis BIO, has introduced two new allograft tissues designed to aid cardiac surgeons in complex procedures.
☑️ @Roche and @BroadGenomics to partner on advancing SBX technology. This partnership aims to revolutionise clinical genomics and biomedical discovery by leveraging the technology.
☑️ New research by @EdwardsLifesci has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms develop improves patient outcomes and reduces the economic and resource burden on healthcare systems.
#InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr
Oxford Brain Diagnostics retweeted
Oxford Brain Diagnostics to launch groundbreaking dementia diagnosis technology pharmatimes.com/news/oxford-…
Oxford Brain Diagnostics retweeted
Oxford Brain Diagnostics initiates dementia diagnostic commercialisation
Rollout plans for the company’s early dementia detection software in the US follow the tool’s FDA clearance in January 2025.
medicaldevice-network.com/ne…
Our CDM Insights has received FDA 510(k) clearance and UKCA self-certification, paving the way for US and UK rollout. The software analyses standard MRI scans to provide objective measures of neurodegeneration, enabling timely dementia diagnosis.
telegraph.co.uk/news/2025/05…
1
55
Oxford Brain Diagnostics retweeted
⏰ It's time to make dementia diagnosis a priority.
#DementiaActionWeek 2025 kicks off today and still one in three people living with dementia in the UK are doing so without a diagnosis.
And we can all do our part to change that. 1/3
We proudly welcome Gail Marcus to our board as Chair Person and we also congratulate Andrew Barker on his retirement from the role and thank him for his 6 years dedicated to leading the Board.
#WelcomeToTheTeam #OxfordBrainDiagnostics #RethinkingBrainHealth
1
47
Cortical Disarray Measurement technology helps to:
- Reduce diagnostic uncertainty
- Enable earlier intervention
- Distinguish between different dementia subtypes
- Make precision diagnostics more widely available
52
Dementia isn't simply a disease of old age. It's the result of pathological processes developing over decades.
We provide sensitive imaging biomarkers to detect subtle changes in brain health across the lifespan, not just when symptoms become apparent.
bit.ly/4cEaorm
35
🌸 Easter Greetings from Oxford Brain Diagnostics! 🐣
We may not be searching for candy-filled eggs anymore, but we can still find excitement and joy as we embrace growth and change in our daily lives.
Let’s continue to stay curious, hopeful and open to the opportunities ahead.
39
Oxford Brain Diagnostics retweeted
Today, 15 April 2025, the European Commission has approved the use of lecanemab in the treatment of early Alzheimer’s disease, the first disease-modifying therapy for Alzheimer’s disease to be made available in the EU27 and EEA Member States.
Learn more on this latest update on our website: bit.ly/4jyTVa3
#Lecanemab #Lequembi #DementiaTreatments #EU















